Document:

Ex 10.41 Insider Trading Policy

Exhibit 10.41

                                    

POLICY OF ENDO INTERNATIONAL plc 
RELATING TO INSIDER TRADING IN COMPANY SECURITIES AND CONFIDENTIALITY OF INFORMATION

To:    All Personnel 
From:     Rajiv De Silva, President & Chief Executive Officer

The Board of Directors has adopted the following Policy which applies to all personnel (including directors and officers) of Endo International plc and its subsidiaries (collectively called the “Company”) arising from our legal and ethical responsibilities as a public company.  

Federal and state securities laws prohibit the purchase or sale of a company’s securities by anyone who is aware of material information about that company that is not generally known or available to the public.  These laws also prohibit anyone who is aware of material nonpublic information from disclosing this information to third parties except in the necessary course of business. Companies and their controlling persons may also be subject to liability if they fail to take reasonable steps to prevent insider trading by company personnel.
1.Prohibition Against Trading on Undisclosed Material Information: 

You are prohibited from engaging in any transaction in the Company’s securities while aware of material non-public information about the Company.  It makes no difference whether or not you relied upon or used material non-public information in deciding to trade – if you are aware of material non-public information about the Company, the prohibition applies.  This prohibition covers virtually all transactions in the Company’s securities, including purchases, sales, pledges, hedges, options and other derivatives, loans and gifts of the Company’s securities, as well as other direct or indirect transfers of the Company’s securities. This prohibition extends to trades of the Company’s securities in which you have any “beneficial” or other interest, or over which you exercise investment control, including: 
		
	•
	transactions in the Company’s securities held in joint accounts or accounts of persons or entities controlled directly or indirectly by you;

		
	•
	transactions in the Company’s securities for which you act as trustee, executor or custodian; and

		
	•
	transactions in any other account or investment involving in any way any the Company’s securities over which you exercise any direct or indirect control.

Specifically, if you are aware of material information relating to the Company which has not yet been available to the public for at least two full days (often called “inside information”), you are prohibited from engaging in any transaction in our securities, directly or indirectly, and from disclosing such information to any other persons, except in the necessary course of business.  Any information, positive or negative, is "material" if it might be of significance to an investor in determining whether to purchase, sell or hold our securities or if it could materially affect the market price or value of our securities. Information may be significant for this purpose even if it 

Exhibit 10.41

would not alone determine the investor's decision. Examples include a potential business acquisition, internal information about revenues, earnings or other aspects of financial performance that departs in any way from what the market would expect based upon prior disclosures, important business developments (including FDA approval or nonapproval of one of our products), the acquisition or loss of major customer, or an important transaction. We emphasize that these examples are merely illustrative. When we refer to our “securities” we mean the Company's common stock and any other securities that the Company may publicly offer such as notes or warrants.

Release of information to the media does not immediately mean the information has become publicly available.  Information is considered to be available to the public only when it has been released broadly to the marketplace (such as by a press release or an SEC filing) and the investing public has had time to absorb and evaluate it.  We do not consider information about the Company to be public until at least two full trading days have passed following its formal release to the market.  Once material information is publicly announced, trading can occur after a lapse of two full trading days. Therefore, if an announcement is made before the commencement of trading on a Monday, an employee may trade in the Company's stock or other securities starting on the Wednesday of that week, because two full trading days would have elapsed by then (all of Monday and Tuesday). If the announcement is made on Monday after trading begins, employees may not trade in the Company's stock or other securities until Thursday. Please consult the Company’s Chief Financial Officer or Chief Legal Officer if you are uncertain when trading may commence following an announcement.

The above prohibition against trading on inside information generally reflects the requirements of law as well as the Company's Policy. As more fully discussed below, a breach of this Policy will likely also constitute a serious legal violation.

2.Restricted Periods: In addition to the limitations set forth in Section 1 above, “Restricted Personnel” are not permitted to trade any Company securities during a “Restricted Period”.  “Restricted Personnel” are those individuals who are at an enhanced risk of possessing inside information.  This group includes all members of the Company’s Board of Directors, all Company officers (Senior Vice Presidents and above), all American Medical Systems Vice Presidents and above, all Paladin Labs Inc. Vice Presidents and above and all Company employees at and above Director level in the following departments: Corporate Affairs, Corporate Development, Finance and Legal.   “Restricted Personnel” are not permitted to trade any securities of the Company during periods that begin 10 trading days prior to the end of each of the Company's fiscal quarters (including its fiscal year end) and ending two full trading days after the financial results for each quarter, or with respect to the fourth quarter for the full year, have been announced publicly (a "Restricted Period"). The Company's fiscal quarters end on each March 31, June 30 and September 30 and its fiscal year end is December 31. The announcement date of the quarterly results varies, but occurs normally within thirty (30) days following the end of the fiscal quarter. For example, if we issued our first quarter earnings before the market opens on April 30th, Restricted Personnel could not trade any securities of the Company from March 15th until May 2nd, which is two full trading days after the first quarter results are publicly announced.

Notwithstanding the foregoing, Restricted Personnel may sell any securities of the Company during a Restricted Period if such securities are sold pursuant to an effective registration statement on Form S-3 or Form S-4 or any successor form thereto 

2

Exhibit 10.41

on file with the U.S. Securities and Exchange Commission (an "Exempted Sale") and such personnel have received the consent of the Company’s Chief Financial Officer or Chief Legal Officer prior to conducting such sale. Furthermore, upon the receipt of a notice by mail, fax or email from the Company informing personnel of an Exempted Sale, all personnel may trade any securities of the Company, if such personnel shall have first received the consent of the Company’s Chief Financial Officer or Chief Legal Officer to conduct such sale, until such time as the Exempted Sale is consummated, but in no case for more than three business days from the date of such notice.

3. Confidentiality Generally: Serious problems arise from the unauthorized disclosure of internal information about the Company (or confidential information about our customers or vendors), whether or not the purpose is to facilitate improper trading in our stock. Accordingly, the Company's confidentiality policy remains the same but is supplemented by this Policy. Company personnel must not discuss internal Company matters or developments with anyone outside of the Company, except in the necessary course of business as required in the performance of regular corporate duties.

This prohibition applies specifically (but not exclusively) to inquiries about the Company that may be made by the financial press, investment analysts or others in the financial community. It is important that all such communications on behalf of the Company be made only through an appropriately designated officer under carefully controlled circumstances. Unless you are expressly authorized to the contrary, if you receive any inquiries of this nature, you should decline comment and refer the inquiry to the Company’s Vice President, Corporate Affairs.  

4. Information About Other Companies: In the course of your employment, you may become aware of material non-public information about other public companies – for example, other companies with which our Company has business dealings. You are prohibited from engaging in any transaction in the securities of any other public company at a time when you are in possession of material non-public information about such company.  You are also prohibited from communicating that information to any other person.

5. Tipping: Improper disclosure of non-public information to another person, whether or not the person engages in a transaction in the stock (so-called "tipping"), is also a serious legal offense by the tipper and a violation of the terms of this Policy. If you disclose information about our Company, or information about any other public company that you acquire in connection with your employment with our Company, you may be fully responsible legally for the trading of the person receiving the information from you (your "tippee") and even persons who receive the information directly or indirectly from your tippee. Accordingly, in addition to your general obligations to maintain confidentiality of information obtained through your employment and to refrain from trading while in possession of such information, you must take utmost care not to discuss confidential or non-public information with family members, friends or others.

6. Limitation on Certain Trading Activities: We encourage interested employees to own securities as a long-term investment at levels consistent with their individual financial circumstances and risk-bearing abilities (since ownership of any security entails risk). However, Company personnel may not engage in 

3

Exhibit 10.41

hedging transactions or trade in puts, calls or similar options on our stock or sell our stock "short".  Additionally, Company personnel may not pledge Company common stock as collateral for a loan, including holding common stock in a margin account.  (You may, of course, exercise any stock options granted to you by the Company in accordance with their terms.) 

7. Consequence of Violation: The Company considers strict compliance with this Policy to be a matter of utmost importance. We would consider any violation of this Policy by an employee as a threat to our reputation. Violation of this Policy could cause extreme embarrassment and possible legal liability to you and the Company. Knowing or willful violations of the letter or spirit of this Policy will be grounds for immediate dismissal from the Company, whether or not your failure to comply with this policy results in a violation of law. Violation of the insider trading laws and this Policy might expose the violator to severe criminal penalties as well as civil liability to any person injured by the violation. For example, under U.S. securities laws, individuals may be subject to imprisonment for up to 20 years, criminal fines of up to $5 million and civil fines of up to three times the profit gained or loss avoided, as well as the attorneys' fees of the persons injured.

8.Resolving Doubts: If you have any doubt as to your responsibilities under this Policy, seek clarification and guidance before you act from the Company’s Chief Financial Officer or Chief Legal Officer. Do not try to resolve uncertainties on your own.

9.A Caution About Possible Inability to Sell: Although the Company encourages employees to own our securities as a long-term investment (See Section 6), all personnel must recognize that trading in securities may be prohibited at a particular time because of the existence of material non-public information. Anyone purchasing our securities must consider the inherent risk that a sale of the securities could be prohibited at a time he or she might desire to sell them. The next opportunity to sell might not occur until after an extended period, during which the market price of the securities might decline.

4

Exhibit 10.41

10.10b5-1 Trading Plans. SEC Rule 10b5-1(c) of the Securities Exchange Act of 1934 permits corporate insiders to establish written trading plans (commonly referred to as “10b5-1 plans”) that can be useful in enabling insiders to plan ahead without fear that they might become exposed to material non-public information that will prevent them from trading.  Where a valid 10b5-1 plan has been established at a time when the insider was not in possession of material non-public information, trades executed as specified by the plan do not violate the securities laws or this policy even if the insider is in possession of material non-public information at the time the trade is executed.  All Restricted Personnel are permitted to establish a 10b5-1 plan.  To qualify as a 10b5-1 plan for purposes of this Policy, the plan must be approved in advance by the Chief Legal Officer, and you should allow at least five business days for that approval.  For more information about how to establish a 10b5-1 plan, please contact the Chief Legal Officer.  The Company reserves the right to disapprove any submitted plan.

Adopted by the Board of Directors of 
Endo International plc  
on April 29, 2014 

*******

5Ex 10.162.1 Susan Hall Amendment

Ex 10.162.1

FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

This First Amendment (this “Amendment”) to Executive Employment Agreement (the “Agreement”) dated as of the 21st day of April, 2014, by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”) and Susan Hall (the “Executive”) is effective as of April 22, 2014 (“Amendment Effective Date”).  The Company and the Executive may be referred to herein individually as a “Party” or collectively as the “Parties.”  All terms not defined herein shall have the meanings ascribed to them in the Agreement.

WHEREAS, the Parties entered into the Agreement to document the terms of the Executive’s employment with the Company as its Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality; and 

WHEREAS, the Parties desire to amend the Agreement to correct an administrative error. 

NOW, THEREFORE, in consideration of the respective agreements of the Parties contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, agree as follows: 

		
	1.
	The Agreement is hereby amended by deleting original Section 5(e) and replacing it with new Section 5(e) which shall read as follows:

(e)    Tax Equalization. The Company agrees to tax equalize Executive in respect of Executive’s monetary remuneration under this Agreement, including Base Salary, all payments and benefits provided under incentive plans and other employee benefit plans, vacation pay, relocation reimbursements, severance pay, tax equalization payments and any other forms of compensation provided pursuant to this Agreement.  Under this tax equalization arrangement, Executive will engage a professional accounting firm reasonably acceptable to the Company with offices in both Ireland and the U.S., the reasonable fees for which shall be paid for by the Company, to prepare notional Irish and U.S. (including Tennessee) tax returns in order to determine, for any particular calendar year, the total Irish and U.S. (and Tennessee) income tax paid or payable in respect of Executive’s monetary remuneration under this Agreement, inclusive of any applicable foreign tax credits which Executive may be legally entitled to claim in the U.S. in respect of taxes paid or payable in Ireland in that period (the “Ireland/U.S. Calculation”).  To the extent that the amount of tax paid or payable under the Ireland/U.S. Calculation for any applicable taxation year exceeds that amount which is paid or payable as income taxes under the U.S. tax calculation, the Company will pay to Executive, as soon as reasonably practicable following such determination, the difference, plus the appropriate gross-up to the extent that such equalization payment itself may be subject to tax in Ireland and/or the 

Ex 10.162.1

U.S.  Such amounts shall each be paid in a lump-sum payment within thirty (30) days of the determination of the applicable amount, and in no event later than April 15th of the calendar year following the year after Executive remitted, or, if earlier, was required to remit, the related taxes.  The overall intent of this provision is that Executive shall be in no better position with respect to taxation and shall, on an after-tax basis reflecting both Irish and U.S. (and Tennessee) taxes paid and payable and any adjustments paid or payable pursuant to this section, receive the same amount of money that Executive would have received had Executive earned such income entirely in and as a permanent resident of Tennessee, but there shall be no adjustment to reflect fluctuating monetary exchange rates.  Executive will be responsible for compliance with all applicable tax laws and regulations and for the payment of all income taxes, property taxes, custom duties, fees, licenses, and other taxes imposed on Executive by any authorities in Ireland, the U.S. or elsewhere.

		
	2.
	Except as expressly amended or otherwise modified hereby, all of the terms, conditions and provisions of the Agreement shall remain in full force and effect.

Ex 10.162.1

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

	
			
	 
	ENDO HEALTH SOLUTIONS INC.

	 
	 
	 

	By:
	/S/ RAJIV DE SILVA

	 
	Name:
	Rajiv De Silva

	 
	Title:
	President & CEO

	 
	 
	 

	 
	EXECUTIVE

	 
	 
	 

	By:
	/S/ SUSAN HALL

	 
	Susan Hall

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]